NCT03695835View on ClinicalTrials.gov

A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen.

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

April 11, 2018

Primary Completion Date

July 8, 2019

Study Completion Date

June 17, 2020

Conditions

Adenocarcinoma

Interventions

DRUG

Immunotherapeutic Agents

Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents

DEVICE

Ablation

Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents

Trial Locations (1)

33301

The Center for High Risk and Recurrent Prostate Cancer, Fort Lauderdale

All Listed Sponsors

lead

Gary Onik MD

INDIV

NCT03695835 - A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen. | Biotech Hunter | Biotech Hunter